Literature DB >> 33886531

Laboratory Modeling of SARS-CoV-2 Exposure Reduction Through Physically Distanced Seating in Aircraft Cabins Using Bacteriophage Aerosol - November 2020.

Watts L Dietrich, James S Bennett, Byron W Jones, Mohammad H Hosni.   

Abstract

Aircraft can hold large numbers of persons in close proximity for long periods, which can increase the risk for transmission of infectious disease.* Current CDC guidelines recommend against travel for persons who have not been vaccinated against COVID-19, and a January 2021 CDC order requires masking for all persons while on airplanes.†,§ Research suggests that seating proximity on aircraft is associated with increased risk for infection with SARS-CoV-2, the virus that causes COVID-19 (1,2). However, studies quantifying the benefit of specific distancing strategies to prevent transmission, such as keeping aircraft cabin middle seats vacant, are limited. Using bacteriophage MS2 virus as a surrogate for airborne SARS-CoV-2, CDC and Kansas State University (KSU) modeled the relationship between SARS-CoV-2 exposure and aircraft seating proximity, including full occupancy and vacant middle seat occupancy scenarios. Compared with exposures in full occupancy scenarios, relative exposure in vacant middle seat scenarios was reduced by 23% to 57% depending upon the modeling approach. A 23% exposure reduction was observed for a single passenger who was in the same row and two seats away from the SARS-COV-2 source, rather than in an adjacent middle seat. When quantifying exposure reduction to a full 120-passenger cabin rather than to a single person, exposure reductions ranging from 35.0% to 39.4% were predicted. A 57% exposure reduction was observed under the vacant middle seat condition in a scenario involving a three-row section that contained a mix of SARS-CoV-2 sources and other passengers. Based on this laboratory model, a vacant middle seat reduces risk for exposure to SARS-CoV-2 from nearby passengers. These data suggest that increasing physical distance between passengers and lowering passenger density could help reduce potential COVID-19 exposures during air travel. Physical distancing of airplane passengers, including through policies such as middle seat vacancy, could provide additional reductions in SARS-CoV-2 exposure risk.

Entities:  

Year:  2021        PMID: 33886531     DOI: 10.15585/mmwr.mm7016e1

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  6 in total

1.  Indoor positioning systems to prevent the COVID19 transmission in manufacturing environments.

Authors:  F Pilati; A Sbaragli; M Nardello; L Santoro; D Fontanelli; D Brunelli
Journal:  Procedia CIRP       Date:  2022-05-26

2.  Assessment of a Biosafety Device to Control Contamination by Airborne Transmission during Orthodontic/Dental Procedures.

Authors:  Josilene Santa Rita de Assis; Aguinaldo Silva Garcez; Hideo Suzuki; Victor Angelo Martins Montalli; Denise Nami Fujii; Michelle Bertini Prouvot; Selly Sayuri Suzuki
Journal:  Int J Dent       Date:  2022-04-15

3.  Identifying mitigation strategies for COVID-19 superspreading on flights using models that account for passenger movement.

Authors:  Sirish Namilae; Yuxuan Wu; Anuj Mubayi; Ashok Srinivasan; Matthew Scotch
Journal:  Travel Med Infect Dis       Date:  2022-03-16       Impact factor: 20.441

4.  SARS-CoV-2 aerosol risk models for the Airplane Seating Assignment Problem.

Authors:  J A Pavlik; I G Ludden; S H Jacobson
Journal:  J Air Transp Manag       Date:  2021-12-03

5.  Effects of nanosized water droplet generation on number concentration measurement of virus aerosols when using an airblast atomizer.

Authors:  Milad Massoudifarid; Amin Piri; Jungho Hwang
Journal:  Sci Rep       Date:  2022-04-21       Impact factor: 4.996

Review 6.  Travel in the Time of COVID: A Review of International Travel Health in a Global Pandemic.

Authors:  Gerard T Flaherty; Davidson H Hamer; Lin H Chen
Journal:  Curr Infect Dis Rep       Date:  2022-08-04       Impact factor: 3.663

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.